



## Compelling Clinical Data Presented on Cholangioscopy at Digestive Disease Week

This year at Digestive Disease Week™ (DDW 2016), more than 30 abstracts were presented on cholangioscopy with a combined total of more than 1,000 patients. Many of the presented abstracts featured one of the newest innovations in endoscopic retrograde cholangiopancreatography (ERCP) technology, the Boston Scientific SpyGlass™ DS Direct Visualization System. An advanced, single-use visualization technology, the SpyGlass DS System offers high-resolution imaging and therapy during ERCP procedures.

### Two studies, in particular, stood out.

**1** A retrospective, multicenter study ("**Digital Single Operator Cholangioscopy (DSOC): Multicenter Experience in 237 Patients**") presented by Dr. Isaac Rajjman of Baylor St. Luke's Medical Center in Houston, TX, USA, examined the diagnostic and therapeutic effectiveness of DSOC. "We found that direct visualization using the SpyGlass DS System enabled us to perform multiple tests during a single procedure, providing us with better intelligence about a patient's pathology and improving our ability to guide treatment decisions," explained Dr. Rajjman. "In fact, in 30 percent of cases, we modified the patient's diagnosis from malignant to benign, a change that allowed these patients to avoid additional and unnecessary intervention. The key takeaway here is that if we use the best available technology and perform procedures like cholangioscopy in a systematic and methodical way, we have the ability to markedly enhance the patient experience and improve outcomes."

**2** Another notable abstract included a retrospective, multicenter study ("**SPYGLASS DS Cholangioscopy for Difficult Stones: Early Experiences of Two UK Centres**") presented by Dr. Richard Sturgess of The Digestive Disease Centre at Aintree University Hospital in Liverpool, UK, and Dr. George Webster of University College Hospital in London, UK. The abstract reports on the early use of the SpyGlass DS System using electrohydraulic lithotripsy (EHL) in patients who have undergone multiple failed ERCPs to attempt stone clearance. "In these complex cases, we were able to achieve definitive stone clearance in 81 percent of patients without any complications or the need for additional or repeat procedures," explained Dr. Webster. "We found that cholangioscopy and intraductal lithotripsy have had a specific role in treating patients with difficult stones due to stone location, size or number. Using the SpyGlass DS System in these procedures significantly increased our ability to reduce the number of repeat ERCPs." Webster added, "The SpyGlass DS System enabled us to more efficiently diagnose and treat difficult stones with or without intervention. When we use the SpyGlass DS System, we are taking preventative measures to help reduce repeat procedures, therefore improving the overall quality of care for the patient."

Since its launch last year, the SpyGlass DS System has **impacted more than 18,000 patient lives in 43 countries**. For case studies, presentations and programs on cholangioscopy, please visit [www.EndoSuite.com](http://www.EndoSuite.com).

### Industry Accolades for the SpyGlass DS System

In November 2015, the SpyGlass DS System won an R&D 100 Award in the Analytical and Test category.

Boston Scientific recently won a Silver 2016 Medical Design Excellence Award (MDEA) for the



SpyGlass DS System in the "**Radiological and Electromechanical Devices**" category. The MDEA recognizes significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.

In addition, the Galien Foundation named the SpyGlass DS System as a finalist for the 2016 Prix Galien USA award in the "**Best Medical Technology**" category. The Prix Galien Award is among the health-innovation industry's most prized honors, and is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research. Winners, selected by a committee of world-renowned leaders from industry and academia, will be announced at a ceremony in October 2016.

ACCESS magazine was produced in cooperation with several physicians. The procedures discussed in this document are those of the physicians and do not necessarily reflect the opinions, policies or recommendations of Boston Scientific Corporation or any of its employees.

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Please check availability with your local sales representative or customer service.

Results from case studies are not predictive of results in other cases. Results in other cases may vary.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority registrations. Material not intended for use in France.

All trademarks are the property of their respective owners.

© 2016 Boston Scientific Corporation or its affiliates. All rights reserved.

ENDO-423703-AA October 2016